1. Home
  2. FOR vs TYRA Comparison

FOR vs TYRA Comparison

Compare FOR & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Forestar Group Inc

FOR

Forestar Group Inc

HOLD

Current Price

$30.31

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$27.99

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOR
TYRA
Founded
2005
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2007
2021

Fundamental Metrics

Financial Performance
Metric
FOR
TYRA
Price
$30.31
$27.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
8
Target Price
$31.75
$42.75
AVG Volume (30 Days)
197.6K
769.6K
Earning Date
01-20-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
3.27
N/A
Revenue
$1,685,000,000.00
N/A
Revenue This Year
$0.52
N/A
Revenue Next Year
$7.72
N/A
P/E Ratio
$9.27
N/A
Revenue Growth
15.89
N/A
52 Week Low
$18.00
$6.42
52 Week High
$30.74
$33.99

Technical Indicators

Market Signals
Indicator
FOR
TYRA
Relative Strength Index (RSI) 71.28 43.87
Support Level $29.13 $24.88
Resistance Level $29.87 $33.99
Average True Range (ATR) 0.95 2.57
MACD 0.32 -0.53
Stochastic Oscillator 93.22 34.14

Price Performance

Historical Comparison
FOR
TYRA

About FOR Forestar Group Inc

Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. the company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: